Show simple item record

dc.contributor.authorEarl, H
dc.contributor.authorHiller, L
dc.contributor.authorHoward, H
dc.contributor.authorDunn, J
dc.contributor.authorYoung, J
dc.contributor.authorBowden, S
dc.contributor.authorMcDermaid, M
dc.contributor.authorWaterhouse, A
dc.contributor.authorWilson, Gregory
dc.contributor.authorAgrawal, R
dc.contributor.authorO'Reilly, S
dc.contributor.authorBowman, A
dc.contributor.authorRitchie, D
dc.contributor.authorGoodman, A
dc.contributor.authorHickish, T
dc.contributor.authorMcAdam, K
dc.contributor.authorCameron, D
dc.contributor.authorDodwell, D
dc.contributor.authorRea, D
dc.contributor.authorCaldas, C
dc.contributor.authorProvenzano, E
dc.contributor.authorAbraham, J
dc.contributor.authorCanney, P
dc.contributor.authorCrown, J
dc.contributor.authorKennedy, M
dc.contributor.authorColeman, R
dc.contributor.authorLeonard, R
dc.contributor.authorCarmichael, J
dc.contributor.authorWardley, Andrew M
dc.contributor.authorPoole, C
dc.date.accessioned2017-06-29T10:06:50Z
dc.date.available2017-06-29T10:06:50Z
dc.date.issued2017-06
dc.identifier.citationAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid28479233
dc.identifier.doi10.1016/S1470-2045(17)30319-4
dc.identifier.urihttp://hdl.handle.net/10541/620398
dc.description.abstractThe tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UKen
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractThe tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.


Files in this item

This item appears in the following Collection(s)

Show simple item record